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1. ABSTRACT 
ALK rearrangement represents a novel molecular target in a subset of non small cell 
lung cancers (NSCLC). Our aim is to explore fluorescence in situ hibridation (FISH) 
and inmunohistochemistry (IHC) as diagnostic methods, prevalence and clinical 
outcomes of ALK rearrangement patients in a selected population of NSCLC. Methods: 
patients with NSCLC previously screened for EGFR mutation at our institution 
bettween June 2006 and January 2010 were selected. ALK rearrangement was identified 
by using FISH and the value of IHC (D5F3 monoclonal antibody-mAb) was explored. 
For IHC ALK protein expression positivity was defined as tumor-specific staining of 
any intensity in ≥10% of the tumor cells. Results: 92 patients were identified. Data is 
available for 71 patients: median age was 61 years (range 36-83), 80% were 
adenocarcinomas, 7% squamous and 13% NOS carcinomas. 51% patients were female. 
All were caucasian. 32% of the patients were never smokers and 30% former smokers. 6 
(8.5%) patients were ALK rearranged positive by FISH, 9 (12.7%) were EGFR mutant, 
and 56 (78.8%) were wild type (WT/WT) for both ALK and EGFR. ALK 
rearrangements and EGFR mutations were mutually exclusive. ALK rearranged patients 
tend to be younger than EGFR mutated or WT/WT patients (median age of 53, 59 and 
62 years, respectively). Patients with ALK positive tumors were predominantly never 
smokers (67%) and adenocarcinomas (83.4%) with equal distribution for sex. ALK 
positive and EGFR mutant patients have a better survival than WT/WT patients 
(p=0.003 and p=0.03). All patients with ALK FISH negative tumors were negative for 
ALK IHC. Out of 6 patients positive for ALK FISH, 4 were also positive for ALK IHC, 
1 negative and in the other there was not enough tissue to perform the analysis. 
Conclusions: The prevalence of ALK rearrangement is 8.5% in a caucasian selected 
population of NSCLC. ALK positive patients have different clinical features and a 
better prognostic than EGFR WT and ALK negative patients. IHC with D5F3 mAb 
against ALK is a promising method for detecting ALK rearranged NSCLC patients 
2. INTRODUCTION 
Lung cancer is the most frequent cause of cancer-related death worldwide, accounting 
for more than 1 million deaths per year.i Although cytotoxic chemotherapy remains the 
mainstay of treatment for the majority of patients with advanced non small cell of 
cancer (NSCLC),ii iii identification of specific genetic lesions that drive the proliferation 
of cancer cells have led to the development of new target therapies in a subset of 
patients with NSCLCiv v. Actually, EGFR (epidermal growth factor receptor) TKI´s 
(tyrosine kinase inhibitors) , gefitinib or erlotinib,  are an option for newly diagnostic 
patients with NSCLC harboring activating mutations in the EGFR TK domainvi vii .  In 
recent years, Anaplastic lymphoma kinase (ALK) rearrangement, predominantly with 
EML4 gene, has been identified as an oncogenic event in a subset of NSCLC patients 
viii. ALK translocation results in the constitutively expression of the tyrosine kinase 
domain of ALK protein, which results in tumor development and growth. The 
oncogenic dependence of this event is demonstrated on the basis that aboling ALK 
kinase activity reverses the malignant pattern and growth. More recently, results of a 
phase 1 trial evaluating an ALK inhibitor, crizotinib, in patients with ALK positive 
NSCLC demonstrated encouraging results ix. Clinical trials with crizotinib and other 
ALK inhibitors in this subset population of ALK positive NSCLC patients are now 
ongoing. 
Initial reports have shown that ALK positive NSCLC patients used to have an 
adenocarcinoma histology, even with signet ring cell pattern. ALK positive patients  
were predominantly non/light smokers and youngers than overall NSCLC patientsx. 
These same clinical and pathological features are present also in patients with EGFR 
mutations, but both genetic events seems to be mutually exclusivexi. In unselected 
patients with NSCLC the prevalence of ALK positivity range from 1% to 7% xii,  but 
more than 30% in patients selected by clinical and genetic features as EGFR WT, 
adenocarcinoma and never smokers x. Its prevalence in a selected European population 
of NSCLC patients it is not yet known. 
However, as ALK has been identified in a subset of patients with NSCLC and its 
particular characterictics has been better elucidated, definition of ALK positivity 
remains a challenging issue. First reports on the prevalence of EML4-ALK 
rearrangements used RT-PCR for detecting patients with this molecular profile, usually 
as a retrospective analyses of resected specimens from patients with NSCLCviii xi. 
However, this method is unable to detect unknown EML4-ALK variants or 
rearrangements with other partners different from EML4. Fluorescence in situ 
hibridation (FISH) with a break apart probe to ALK is the diagnostic method for 
selecting patients in crizotinib trials. This method allows detecting ALK translocations, 
no matters the partner or the variant, but ALK positivity definition by FISH and its  
restricted use to resection or biopsy specimens are limitationsxiii. Inmunoshistochemistry 
(IHC) has also been explored. IHC analyses with previous antibodies against ALK 
protein used in hematologic malignances have shown poor sensitivity in detecting this 
protein in patients with NSCLC, probably due to the lower protein levels expressed 
compared to hemathologic malignances with ALK rearrangements. New high 
sensitivity monoclonal antibody D5F8 seems to have accuracy enough to identify 
patients in a more worldwide reproducibility manner xiv, as all patients in which there 
was tissue enough in phase 1 crizotinib trial previously selected by FISH positivity were 
also positive by IHC, whereas only two of three parts of that patients were positive by 
RT-PCR. FISH-negative samples and normal lung tissues did not express ALK protein 
by IHCix.  
The aim of this study is to explore the prevalence of ALK positivity in an European 
cohort of selected NSCLC patients by FISH, define its clinical features and outcomes 
and explore IHC as diagnostic method for NSCLC testing for ALK. 
 
3. MATERIAL AND METHODS: 
Patients 
All included  patients had received treatment or consultation from the Medical 
Oncology Service at Vall d´Hebron University Hospital. Since to, all non small cell 
lung cancer patients previously screened for EGFR status were selected. EGFR 
mutational analyses had been performed based on a medical case per case indication, 
taking into account  gender, histology and smoking history but without fixed 
parameters. Medical records were revised and basal clinicopathological features, 
treatments and outcomes were recorded. If tissue available for ALK analyses, patients 
were first tested by FISH and, subsequently, by IHC. An institutional ethic committee 
approved protocol. 
ALK FISH and ALK IHC testing 
Unstained slides from formalin-fixed, paraffin-embedded (FFPE) tumor samples from 
biopsies or cell blocks reconstructed from cytology or, if not other tissue available, 
slides from cytology  were then analyzed. To identify ALK rearrangements, FISH was 
performed by using a break-apart probe to ALK (Vysis LSI ALK Dual Color, Break 
Apart Rearrangement Probe; Abbott Molecular). Samples were deemed to be FISH-
positive if more than 15% of scored tumor cells had split ALK5´and 3´probe signals or 
had isolated 3´signals. For inmunohistochemistry analyses, rabbit monoclonal antibody 
(mAb) D5F3 was applied. Samples were deemed to be IHC-positive if a tumor-specific 
staining of any intensity in ≥10% of the tumor cells were present. 
Statistical analyses 
Unless otherwise specified, for the analyses of clinical and molecular markers on the 
patient samples, the Fisher´s exact test was used to assess correlation between 
categorical variables and Student´s t test was used to assess association between the 
distributions of treatment outcome. All reported p values are two-sided unless otherwise 
specified, and we considered a test as statistically significant if p≤0.05. To compare the 
correlation between FISH and IHC to detect ALK positive patients we used a kappa 
method  
 
4. RESULTS 
Between May 2006 and January 2010 99 patients previously screened for EGFR 
mutations and with tissue available for ALK analyses by FISH were identified. Data is 
available for 71 patients.  
Of the 71 tumor samples screened, 9 patients (12.7%) harbored an activating EGFR 
mutation, 6 patients (8.5%) were ALK positive and 56 patients (78.8%) were wild type 
and negative for EGFR and ALK.  
Basal characteristics of the patients are summarized in table 1. Patients were 
predominantly adenocarcinomas (80%), never/former smokers (62%) and females 
(51%).  
Consistent with previous studies EGFR mutation and ALK positivity were mutually 
exclusive (table 2). 
ALK positive patients tend to be younger (53 years) than EGFR mutant (59 years) or 
EFGR WT/ALK negative (62 years) patients. There was not a gender prevalence for 
ALK positive patients (3 males and 3 females). All ALK positive patients had a non 
squamous histology, 5 of 6 patiemts were adenocarcinoma and the other had a NOS 
NSCLC. EGFR mutant patients were also predominantly adenocarcinomas but most of 
them were women.  
We also explored the best clinical response with an EGFR TKI or platinum based 
chemotherapy regimen in patients with ALK positive, EGFR mutant or EGFR 
WT/ALK negative metastatic disease. As expected, ALK positive patients treated with 
erlotinib had no objective responses; compared with a 75% of responses for EGFR 
mutant patients and no responses for EGFR WT/ALK negative patients. Responses to 
first line platinum doublet were 25% for ALK positive patients, 60% for EGFR mutant ( 
patients and 40% for EGFR WT/ALK negative.  
At the time of review, median follow-up of patients with metastatic NSCLC was 9.5  
months. We analyzed overall survival (OS) of patients according to ALK and EGFR 
genotype. The median OS were 4.5 months for EGFR WT/ALK negative, and had been 
not reached for ALK positive and EGFR mutant patients. Four of the 6 ALK positive 
patients included in this analyses had received crizotinib as part of their treatment at 
sometime in the course of their disease. 
Finally, we performed an ALK IHC with the D5F8 antibody in the 64 patients in which 
there was material still available. All of 59 patients negative for ALK by FISH were 
also negative for IHC. Of five ALK FISH positive patients tested for IHC, 4 were 
positive, one negative.  
 
5. DISCUSSION 
ALK activation had been identified as a driver oncogene alteration in a subset of 
NSCLC patients. This genetic alteration , mostly associated with rearrangements in the 
same chromosome arm with EML4 gene, is an example of oncogenic dependence. ALK 
positive patients had a predominantly clinicopathological features as adenocarcinoma 
histology, never/light smoking history and younger age at diagnosis. Developement of 
new drugs targeting this alteration, consisting in constitutively activation of ALK kinase 
domain, led to impressive tumor responses in this subset of patients. 
In our report, we select a subset of patients treated or having consultation at our 
institution on the basis that previously determination of EGFR status would let as to 
identify a population of patients more suitable to harbor an ALK alteration, as both 
population has similar clinical features. 
In this cohort, the prevalence of EGFR mutations were 12.7%, which is close to the 
frequency reported by the Spanish lung cancer group in a similar population. ALK 
positivity was 8.5%,  as expected by publications of other investigator in this population 
of patients and being the first ALK prevalence report in a cohort of predominantly 
metastatic and clinically selected european NSCLC patients. 
ALK positive patients tend to be younger than EGFR mutant and EGFR WT/ ALK 
negative patients without a gender preference. However, the vast majority were 
adenocarcinoma and never/former smokers but this characteristics could be a bias due to 
the basal clinical selection to perform EGFR analyses. 
As previously reported, ALK positive patients had no responses to EGFR TKI and had a 
similar benefit from chemotherapy. Although previous reports have suggest that 
pemetrexed could be the preferred drug for ALK patientsxv, due to the small size of our 
ALK population we were not capable to perform the analyses.  
In the survival analyses, ALK positive and EGFR mutant patients (median survival not 
reached in both groups) have a significant improve in survival compared to EGFR 
WT/ALK negative patients (median survival 4.5 months) (p=0.033 and p=0.003, 
respectively). The median survival in the global cohort was 9.5 months, which is in the 
normal range of a metastatic serie of patients. However, this cohort could be enriched 
by patients with poor performance status or more comorbidities than general population 
of lung cancer patients. Reasons for this hypothesis are that patients suitable to be 
included in a trial had EGFR tested in a central laboratory or patients with good 
performance were included in more trials requiring tissue for biomarkers analyses, not 
being available for this study. This is encouraged suggested by the poor median survival 
in the EGFR WT/ALK negative group (4.5 months). 
IHC exploratory analyses with D5F3 antibody was performed in 64 patients. All 
patients with ALK FISH negative tumors were negative for ALK IHC. Out of 6 patients 
positive for ALK FISH, 4 were also positive for ALK IHC, one negative and in the 
other there was not enough tissue to perform the analysis. The reason for one false 
negative result has to be elucidate but a possible explanation could be the heterogeneity 
of the tumor, as previously suggested by other investigatorsxvi. However, this antibody 
seems to have enough accuracy to asses a positive result for selecting patients to 
treatment with ALK inhibitors. 
6. CONCLUSSIONS 
ALK positive NSCLC represents a 8.5% of patients in a clinical selected population. 
ALK positive patients have a clinical and pathological features useful to select patients 
more suitable to harboring this genetic alteration. At least, in the era of ALK inhibitors 
this biomarker analyses seems to be relevant for prognosis. IHC with D5F3 antibody 
seems to be accuracy enough for selecting patients for treatment with ALK inhibitors. 
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